AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00744666
Drug: Prednisolone 1% topical eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1% 1gtt qid to the eye requiring IVTA
Trial: NCT00180167
Drug: randomization between two established Chemotherapies
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02103374
Drug: Atrovent + Bricanyl or Atrovent + Ventoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
Trial: NCT02103374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule lactose during 48 weeks
Trial: NCT03612323
Drug: Intra-ligamentary Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
Trial: NCT03002454
Drug: 99mTc MDP Injection:neutron-bombardment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
Trial: NCT03734068
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is loaded to LIfePearl
Trial: NCT02546960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
Trial: NCT00579995
Drug: Oral N-Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 milligrams (mg)
Trial: NCT04515953
Drug: ND-340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
Trial: NCT04515953
Drug: IV-PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
Trial: NCT01400932
Drug: GI148512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
Trial: NCT01400932
Drug: vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
Trial: NCT01263015
Drug: Atripla placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo taken once daily on an empty stomach
Trial: NCT01565395
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile preservative free 0.9% saline
Trial: NCT03659058
Drug: silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silymarin 140 three times daily
Trial: NCT03659058
Drug: Antioxidants
RxNorm normalized name: E Complex with Antioxidants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
Trial: NCT02736513
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive AZD9291 at a dose of 80 mg once daily.
Trial: NCT02566356
Drug: Saline Nasal Spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Trial: NCT00046930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored.
Trial: NCT04373473
Drug: PRIM-DJ2727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
Trial: NCT04373473
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
Trial: NCT02482402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation solution placebo
Trial: NCT04411537
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During neo-CRT: 625mg/m2 bid Monday-Friday per week
Trial: NCT00391001
Drug: Taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: double-blind, placebo-controlled, adjunctive medication
Trial: NCT01898156
Drug: BIW-8962
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops.
Trial: NCT02472847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
Trial: NCT03542851
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be presented as oral capsule.
Trial: NCT00568113
Drug: acetylcysteine in arm 1
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy.
Trial: NCT00121134
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once a day for 6 months
Trial: NCT00121134
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice daily for the first two days of every week for 6 months
Trial: NCT00121134
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)
Trial: NCT03909451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT01363934
Drug: GC1113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.
Trial: NCT00997620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
Trial: NCT00154362
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00506194
Drug: OAD
RxNorm normalized name: Toad toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide-MR, Metformin, Glimepiride
Trial: NCT03600454
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol
Trial: NCT03600454
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid
Trial: NCT02257723
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
Trial: NCT01048866
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
Trial: NCT01048866
Drug: flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
Trial: NCT01048866
Drug: acetaminophen 650mg
RxNorm normalized name: ACETAMINOPHEN 650MG TAB
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication to be taken as needed. Rescue medication was not blinded.
Trial: NCT00722202
Drug: ERB-257
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02102152
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00554099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
Trial: NCT00554099
Drug: Antibiotic for Diverticulitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
Trial: NCT02922166
Drug: SRX246
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT02922166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT02761694
Drug: Vevorisertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an oral dose every day or every other day.
Trial: NCT00450736
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00907296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT00099281
Drug: YMB 1002
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02238340
Drug: ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02238340
Drug: dipirone
RxNorm normalized name: dipyrone
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01916850
Drug: LX4211 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01916850
Drug: LX4211 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01916850
Drug: LX4211 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00707746
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02787590
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02787590
Drug: Matched Placebo (for Simvastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03770494
Drug: LY3405105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00316888
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01883427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo containing saline+glucose
Trial: NCT05239221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution visually matching active medication
Trial: NCT01386736
Drug: Placebo drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
Trial: NCT01968577
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 40 mg before percutaneous coronary intervention
Trial: NCT00983736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks.
Trial: NCT02570243
Drug: High dose of Unfractionated Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin 100IU/Kg
Trial: NCT02570243
Drug: Standard dose of Unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 50IU/Kg
Trial: NCT04047420
Drug: TAF/EVG Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF/EVG Insert (20/16 mg) administered rectally by study staff
Trial: NCT03757130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to AMG 598 administered by subcutaneous injection
Trial: NCT00700856
Drug: add-on sulphonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
Trial: NCT02750384
Drug: DSM265 50% SDD granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose 400 mg
Trial: NCT02750384
Drug: DSM265 25% SDD powder for suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose 400 mg
Trial: NCT02608450
Drug: CB-03-01 cream, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Trial: NCT02608450
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Trial: NCT00170989
Drug: valsartan plus hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00625612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
Trial: NCT04589143
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
Trial: NCT02609945
Drug: CVT-427 (zolmitriptan inhalation powder),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
Trial: NCT01840254
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00533650
Drug: MK0429
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02576860
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel
Trial: NCT03727412
Drug: Drugs, Generic (Naprosyn)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
Trial: NCT03727412
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
Trial: NCT00649675
Drug: Meloxicam Tablets 15 mg
RxNorm normalized name: meloxicam Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg, single dose fed
Trial: NCT00649675
Drug: Mobic® Tablets 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg, single dose fed
Trial: NCT00714519
Drug: Xenaderm® Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical, BID or as needed
Trial: NCT00714519
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical, BID or as needed
Trial: NCT02910167
Drug: Hyoscine n-butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine n-butylbromide 10 mg
Trial: NCT00149942
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02642432
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-493 coformulated with ABT-530
Trial: NCT00477269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00260858
Drug: Test Meal: Reference food (glucose or white bread)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00260858
Drug: Test Meal: Pirate's Booty
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00260858
Drug: Test Meal: Ceaprove wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00087451
Drug: AP23573
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ridaforolimus
Trial: NCT03762382
Drug: TFV/LNG IVR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
Trial: NCT03762382
Drug: TFV IVR
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
Trial: NCT03762382
Drug: Placebo IVR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
Trial: NCT04445623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of placebo daily for 15 days
Trial: NCT02225912
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03780959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered twice weekly by subcutaneous injection
Trial: NCT03689244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets without active compound
Trial: NCT01276821
Drug: L-Epinephrine and Normal Saline (0.9%)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
Trial: NCT01276821
Drug: L-Epinephrine and Hypertonic Saline (3%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
Trial: NCT00595933
Drug: mouth spray
RxNorm normalized name: Moi-Stir Dry Mouth Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
Trial: NCT00595933
Drug: mouth spray
RxNorm normalized name: Moi-Stir Dry Mouth Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
Trial: NCT01363583
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-1.5 ml/hour during 4 days
Trial: NCT03426631
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule 30 minutes before sleep
Trial: NCT03426631
Drug: DAW1033B2 oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAW1033B2 capsule 30 minutes before sleep
Trial: NCT02018874
Drug: LY2780301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D.
Trial: NCT01195688
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral doses given to 2 subjects per dose group